<DOC>
	<DOC>NCT02056080</DOC>
	<brief_summary>A retrospective, observational, not EPA, multicenter study to evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib between January 2005 and December 2011</brief_summary>
	<brief_title>Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Confirmed diagnosis of metastatic breast cancer HER2positive phenotype (confirmed by IHC 3 + or FISH positive) Older than 18 years Progressed to at least one prior treatment line for MBC with trastuzumab and / or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes Having the patient's complete medical history that contains all lines antiHER2 therapy treatment Being a patient who initiated the combination of trastuzumab and lapatinib between January 2005 and December 2011 Inform the patient and get the signature of the informed consent Not having phenotypic classification of the tumor by IHC or FISH test for HER2 Being a patient with HER2negative phenotype(FISH negative or IHC in range [02 +] without FISH) Being a patient who received the trastuzumab and/or lapatinib treatment (TL) in combination with chemotherapy Being a patient who, since January 2012, began TL therapy for metastatic disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Breast Neoplasm</keyword>
	<keyword>Receptor,HER2</keyword>
	<keyword>Antineoplastic agent</keyword>
	<keyword>Antibodies, monoclonal</keyword>
	<keyword>Trastuzumab, Lapatinib</keyword>
	<keyword>Protein kinase inhibitors</keyword>
	<keyword>quinazolines</keyword>
</DOC>